BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 10070304)

  • 1. Markers of bone resorption in patients treated with pamidronate.
    Lipton A; Demers L; Curley E; Chinchilli V; Gaydos L; Hortobagyi G; Theriault R; Clemens D; Costa L; Seaman J; Knight R
    Eur J Cancer; 1998 Dec; 34(13):2021-6. PubMed ID: 10070304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover.
    Rosen HN; Dresner-Pollak R; Moses AC; Rosenblatt M; Zeind AJ; Clemens JD; Greenspan SL
    Calcif Tissue Int; 1994 Jan; 54(1):26-9. PubMed ID: 8118749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
    Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
    J Clin Oncol; 1997 Jan; 15(1):131-8. PubMed ID: 8996134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links.
    Randall AG; Kent GN; Garcia-Webb P; Bhagat CI; Pearce DJ; Gutteridge DH; Prince RL; Stewart G; Stuckey B; Will RK; Retallack RW; Price RI; Ward L
    J Bone Miner Res; 1996 Aug; 11(8):1176-84. PubMed ID: 8854254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic effects of single-dose pamidronate administration in prostate cancer patients with bone metastases.
    Berruti A; Dogliotti L; Tucci M; Tarabuzzi R; Guercio S; Torta M; Tampellini M; Dovio A; Poggio M; Scarpa RM; Angeli A
    Int J Biol Markers; 2002; 17(4):244-52. PubMed ID: 12521128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.
    Lipton A; Cook R; Saad F; Major P; Garnero P; Terpos E; Brown JE; Coleman RE
    Cancer; 2008 Jul; 113(1):193-201. PubMed ID: 18459173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of pamidronate on excretion of pyridinium crosslinks of collagen after total hip arthroplasty.
    Wilkinson JM; Jackson B; Eastell R
    Calcif Tissue Int; 2003 Oct; 73(4):326-31. PubMed ID: 12874697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy.
    Body JJ; Dumon JC; Gineyts E; Delmas PD
    Br J Cancer; 1997; 75(3):408-12. PubMed ID: 9020487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease.
    Vinholes JJ; Purohit OP; Abbey ME; Eastell R; Coleman RE
    Ann Oncol; 1997 Dec; 8(12):1243-50. PubMed ID: 9496390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease.
    Coleman RE; Houston S; James I; Rodger A; Rubens RD; Leonard RC; Ford J
    Br J Cancer; 1992 May; 65(5):766-8. PubMed ID: 1586605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of a point of care device for monitoring the bone resorption biomarker urinary N-telopeptide in cancer patients with bone metastases.
    Lester JE; Brown JE; Hannon RA; Ellis SP; Horsman JM; Purohit OP; Coleman RE
    Bone; 2010 Mar; 46(3):801-5. PubMed ID: 19931437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
    Cremers SC; Papapoulos SE; Gelderblom H; Seynaeve C; den Hartigh J; Vermeij P; van der Rijt CC; van Zuylen L
    J Bone Miner Res; 2005 Sep; 20(9):1543-7. PubMed ID: 16059626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.
    Lipton A; Cook RJ; Major P; Smith MR; Coleman RE
    Oncologist; 2007 Sep; 12(9):1035-43. PubMed ID: 17914073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates and breast carcinoma.
    Lipton A
    Cancer; 1997 Oct; 80(8 Suppl):1668-73. PubMed ID: 9362434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease.
    Engler H; Koeberle D; Thuerlimann B; Senn HJ; Riesen WF
    Clin Chem Lab Med; 1998 Nov; 36(11):879-85. PubMed ID: 9877095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status.
    Costa L; Demers LM; Gouveia-Oliveira A; Schaller J; Costa EB; de Moura MC; Lipton A
    J Clin Oncol; 2002 Feb; 20(3):850-6. PubMed ID: 11821470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma.
    Terpos E; Viniou N; de la Fuente J; Meletis J; Voskaridou E; Karkantaris C; Vaiopoulos G; Palermos J; Yataganas X; Goldman JM; Rahemtulla A
    Eur J Haematol; 2003 Jan; 70(1):34-42. PubMed ID: 12631257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of bone metabolic markers in the diagnosis of bone metastasis from lung cancer.
    Chung JH; Park MS; Kim YS; Chang J; Kim JH; Kim SK; Kim SK
    Yonsei Med J; 2005 Jun; 46(3):388-93. PubMed ID: 15988811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses.
    Lipton A; Cook R; Brown J; Body JJ; Smith M; Coleman R
    Clin Oncol (R Coll Radiol); 2013 Apr; 25(4):217-26. PubMed ID: 23219232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of bone-turnover metabolites in the diagnosis of bone metastases in patients with lung carcinoma.
    Izumi M; Nakanishi Y; Takayama K; Kimotsuki K; Inoue K; Wataya H; Minami T; Hara N
    Cancer; 2001 Apr; 91(8):1487-93. PubMed ID: 11301396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.